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Abstract
A single nucleotide polymorphism (SNP) rs6983267, located within the 8q24 region, is strongly
associated with risk of colorectal and prostate cancer. It has been suggested that the mechanism
of this association is related to differential interaction of TCF7L2 protein (previously known as
TCF-4) with alleles of rs6983267, influencing the expression of a well-known oncogene, MYC,
located 335 Kb telomeric. Here, we tested the correlation between mRNA expression of MYC and
several alternatively spliced forms of TCF7L2 in 117 non-cancer colon samples. We observed a
strong correlation (r = 0.60, p < 10-6) between expression of MYC and a unique splicing form of
TCF7L2. The level of MYC expression in these samples was associated with expression of some
TCF7L2 splicing forms but not with genotypes of rs6983267, or interaction of rs6983267 with
TCF7L2 expression. These findings suggest that some splicing forms of TCF7L2 may be functionally
important for regulation of MYC expression in colon tissue but this regulation is not directly
dependent on rs6983267.
Findings
Recent genome-wide association studies (GWAS) have
identified a single nucleotide polymorphism (SNP)
rs6983267 within the 8q24 region associated with
increased susceptibility to colorectal and prostate cancer
[1-6]. Follow-up association studies have suggested that
the same variant may also increase the risk for cancers of
the kidney, thyroid and larynx [7,8]. The location of
rs6983267 in the intergenic region 335 Kb upstream from
the MYC gene, a well-known oncogene [9], generated a
hypothesis that this SNP might be involved in a long-dis-
tance regulation of MYC expression. Located in a region
with significant evolutionary conservation and enhancer
potential [10-12], the SNP was predicted to affect a bind-
ing site for TCF7L2 [10,11], a key transcription factor in
the WNT pathway. The risk allele G of rs6983267 was
found to have a slightly stronger affinity to TCF7L2 in
binding assays compared to the non-risk allele T, and
stronger regulatory activity in luciferase reporter assays
[10,11]. An analysis of long-range interactions showed
that the region containing rs6983267 might be in physical
proximity with MYC region [10]. These findings suggested
that rs6983267 might be located within an enhancer ele-
ment that interacts with TCF7L2 and regulates MYC
expression [10,11]. MYC is a target gene of TCF7L2 [13-
15] and its expression is regulated through two TCF7L2
binding sites within the MYC promoter [13]. No associa-
tion has been found between rs6983267 and the mRNA
expression of MYC in lymphoblastoid cell lines [11,16],
normal and tumor colon samples [10,11,17-20], or with
MYC immunostaining in colon tumors [5].
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Previously, we performed a detailed study of TCF7L2
expression in several types of human tissue, including
colon where we measured the expression of multiple
assays targeting the majority of known splicing forms of
TCF7L2 [21,22]. In the current study we sought to deter-
mine, whether the expression of TCF7L2 splicing forms
we identified in non-cancer colon samples correlated with
MYC expression and whether this expression was depend-
ent on alleles of rs6983267 or interaction of rs6983267
with TCF7L2 expression.
We investigated non-cancer colon samples on the
assumption that the effect of a germline genetic variation
might be more easily detectable in conditions not affected
by the effects of cancer or its treatment. The samples and
the methods are described in Additional file 1. The mRNA
expression of MYC was detected by sensitive quantitative
reverse-transcriptase PCR (qRT-PCR) and 3 expression
assays (Figure 1A.) The expression of MYC assays 1 and 2,
corresponding to exons 2-3, and 1-2, respectively (RefSeq
transcript NM_002467), was highly correlated (r = 0.95).
MYC assay 3 targeted an alternative transcript initiated
from a promoter P0 (GenBank accession number
M13929) [23], however, expression of this transcript was
very low (at a level of at least 100 times lower than of
assays 1 and 2) and was not studied further. Expression of
TCF7L2 was measured with 7 assays previously described
(Figure 1B, Additional file 2) [21,22].
The strongest correlation between MYC  and  TCF7L2
expression was observed for assay "ex13-14" of TCF7L2 (r
= 0.57- 0.60, p < 10-6), followed by assay "ex11-13" (r =
0.52-0.54, p < 10-6). The weakest correlation was detected
for assay "ex11-13a" (r = 0.10 - 0.15, p = 0.12 - 0.28)
(Table 1). These assays detect alternative splicing forms
that include combinations of exons 11-13-14 and 11-13a-
Location of MYC and TCF7L2 expression assays Figure 1
Location of MYC and TCF7L2 expression assays. A. 
MYC exons and 5' and 3'untranslated regions (UTRs) are 
marked by rectangles and two translation starts are marked 
by vertical lines and arrows. MYC assay1 is located over the 
junction of exons 2 and 3, and MYC assay 2 is located over 
the junction of exons 1 and 2. MYC assay 3 targets alternative 
transcript with an upstream exon. B. Constitutive exons of 
TCF7L2 are represented as black rectangles and alternative 
exons as white rectangles. Protein domains are indicated 
above corresponding exons: β-catenin binding domain is 
encoded by exons 1 and 2, high mobility group (HMG) DNA-
binding domain is encoded by exons 9 and 10 and the 
CRARF DNA-binding domain is encoded by exons 13 and 
14. Location of expression assays is indicated under corre-
sponding exons and arrows show primer positions. The spe-
cificity of detection of particular splicing forms is achieved by 
probes located over exon junctions.
Detailed structure of C-terminal part of TCF7L2 gene Figure 2
Detailed structure of C-terminal part of TCF7L2 
gene. A. Combinations of exons 11, 13, 13a and 14 of 
TCF7L2 encoding proteins with long reading frames (E-tail). 
B. A form with alternative exon 13 encodes a protein 
sequence with CRARF motif; a form with alternative exons 
13a encodes a protein sequence with CRALF motif, differ-
ences in amino acids in proteins encoded by exons 13 and 
13a are underlined, CRARF and CRALF motifs are boxed. C. 
Expression of a splicing form with exon13 correlates with 
MYC expression (r = 0.60, p < 10-6), while expression of a 
splicing form with exon 13a does not correlate with MYC 
expression (r = 0.15, p = 0.12).




MYC assay 1 MYC assay 2
r* p-value# r* p-value#
TCF7L2 TSS1 0.23 0.014 0.21 0.023
TCF7L2 ex3a-4 0.17 0.070 0.15 0.12
TCF7L2 ex7-8 0.38 2.4 × 10-5 0.34 2.1 × 10-4
TCF7L2 ex11-13a 0.15 0.12 0.10 0.28
TCF7L2 ex11-14 0.40 1.2 × 10-5 0.34 2.5 × 10-4
TCF7L2 ex11-13 0.54 <10-6 0.52 <10-6
TCF7L2 ex13-14 0.60 <10-6 0.57 <10-6
*Spearman correlation coefficient and # two-sided p-values for MYC and TCF7L2 
expression in 117 colon samples, p-values are not adjusted for multiple testsMolecular Cancer 2009, 8:96 http://www.molecular-cancer.com/content/8/1/96
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14 in the C-terminal end of the TCF7L2 transcripts (Gen-
Bank accession numbers FJ010174 and FJ010167). Both
protein isoforms encoded by these splicing forms have
long C-terminal reading frames (E-tails) with binding
sites for the C-terminal binding protein (CtBP) involved
in post-translational regulation of TCF7L2 expression
[21,22]. Protein fragments encoded by the alternative
exons 13 and 13a share 68% identity (17 amino acids of
25, Figure 2). The form with exons 11-13-14 encodes a 30-
amino-acid highly conserved motif with a CRARF signa-
ture protein sequence, while in the form with exons 11-
13a-14 this sequence is changed to CRALF (Figure 2). The
CRARF protein sequence is also found in another member
of TCF/LEF family of transcription factors, TCF-7 (former
TCF-1) and in the ancestral drosophila TCF/pangolin pro-
tein [24]. The CRARF sequence serves as an additional
DNA-binding domain and a strong transactivator of the
WNT pathway [24,25]. The CRARF-form of TCF7L2 was
shown to interact with two TCF7L2 binding sites within
MYC promoter, TBE1 at -1156 bp and TBE2 at -589 bp
upstream the first translation start site [13,24]. Therefore,
we suggest that while both the CRARF and CRALF forms
of TCF7L2 contain E-tails, only the CRARF form regulates
MYC expression in the colon. A splicing form detected by
assay "ex11-14" is the most common splicing form of
TCF7L2 in all human tissues [21,22]. This splicing combi-
nation utilizes an alternative stop codon in the beginning
of exon 14 resulting in a protein without the CtBP-bind-
ing domain. A somatic frameshift mutation in a polyA
stretch within exon 14 found in colorectal cancer cell lines
results in similar outcome - termination of protein by an
alternative stop codon in the beginning of exon 14
Table 2: Association of rs6983267 with MYC expression in colon tissue






TCF7L2 TSS1 0.054 0.076
rs6983267*TCF7L2 TSS1 0.91 0.91
age 0.069 0.062
Rs6983267 1.00 0.97
TCF7L2 ex3a-4 0.36 0.52
rs6983267*TCF7L2 ex3a-4 0.93 0.77
Age 0.31 0.39
Rs6983267 0.75 0.28
TCF7L2 ex7-8 0.0039 0.021
rs6983267*TCF7L2 ex7-8 0.79 0.25
age 0.045 0.037
Rs6983267 0.95 0.90
TCF7L2 ex11-13a 0.31 0.50
rs6983267*TCF7L2 ex11-13a 0.97 0.89
age 0.38 0.37
Rs6983267 0.70 0.61
TCF7L2 ex11-14 0.0008 0.013
rs6983267*TCF7L2 ex11-14 0.57 0.50
age 0.13 0.19
Rs6983267 0.22 0.41
TCF7L2 ex11-13 <0.0001 <0.0001
rs6983267*TCF7L2 ex11-13 0.29 0.48
age 0.25 0.27
Rs6983267 0.28 0.30
TCF7L2 ex13-14 <0.0001 <0.0001
rs6983267*TCF7L2 ex13-14 0.35 0.35
*p-values for univariate regression analysis including 0, 1 and 2 alleles of rs6983267 and expression of MYC assays 1 and 2 in the presence of covariates -- age and level of 
expression of TCF7L2 assays or interaction between rs6983267 and TCF7L2 expression; p-values are not adjusted for multiple tests; a genotypes were available for 96 
samples; b age and genotypes were available for 79 samples.Molecular Cancer 2009, 8:96 http://www.molecular-cancer.com/content/8/1/96
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[26,27]. We found a moderate correlation between assay
"ex11-14" of TCF7L2  and  MYC  expression (Table 1).
Next, we evaluated the levels of mRNA MYC expression in
colon tissue in relation to genotypes of rs6983267. We
observed significant effect of age, of several TCF7L2 splic-
ing forms but no effect of rs6983267 alone or in interac-
tion with TCF7L2 (Table 2).
Our results show a strong role of TCF7L2 in regulation of
MYC expression in colon, but not through rs6983267.
Both TCF7L2 and MYC genes are expressed in colon and
are important for maintaining proliferation of intestinal
epithelium [28,29] (Additional file 3). Inactivation of the
adenomatous polyposis coli (APC) tumor suppressor
gene leads to formation of β-catenin/TCF7L2 complexes,
constitutive activation of the WNT pathway and eventu-
ally colorectal cancer. Rare point mutations within
TCF7L2 are also found in colorectal cancers [30]. The pro-
liferative effect of TCF7L2 is achieved through its tran-
scriptional regulation of several target genes such as MYC
and  CCND1  (Cyclin D1)[31]. Our results suggest that
expression of MYC in colon tissue is most likely regulated
by a splicing form of TCF7L2 encoding a protein with a
potent transactivation CRARF-domain. However, we did
not find any evidence for an effect of rs6983267 on
TCF7L2 regulation of MYC expression. Of the family of
TCF/LEF transcription factors, TCF7L2  has the highest
expression in colon, but other members of this family
may also be involved. Inactivation of TCF-7 (former TCF-
1) leads to development of intestinal polyps [32]. Expres-
sion of LEF1 is found in tumors but not in normal colon
tissue [33]. Each of these proteins can recognize the same
TCF/LEF consensus binding site and, therefore, might
bind alleles of rs6983267. High degree of similarity
between TCF/LEF proteins may lead to cross-reactivity in
chromatin immunoprecipitation (ChIP) assays. Thus,
other TCF/LEF factors should also be examined for their
effect on regulation of MYC expression.
In conclusion, SNP rs6983267 within the 8q24 region has
been established as one of the strongest genetic risk fac-
tors for development of at least two types of cancer. Iden-
tification of functional mechanisms of this association is
the highest priority of cancer genetics and would mean a
significant step forward towards understanding of cancer
pathogenesis and development of better diagnostic and
therapeutic approaches. Our results provide new insights
into the regulation of MYC expression by TCF7L2. How-
ever, further studies are needed to investigate alternative
molecular mechanisms that can explain the association
between rs6983267 and cancer risk.
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